At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
HL036 ophthalmic solution +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of Two Concentrations (0.10%, 0.25%) of HL036 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye
In Brief
A Phase 2 clinical trial evaluating HL036 ophthalmic solution and Placebo vehicle solution for Dry Eye. Completed, enrolled 150 participants across 2 sites.
Detailed Summary
The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedNov 2017
Primary CompletionApr 2018
TodayJul 2026
First PostedNov 7, 2017
Enrollment StartNov 5, 2017
Primary CompletionApr 9, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.7 years ago
Interventions
HL036 ophthalmic solutionbiological
HL036 ophthalmic solution
Placebo vehicle solutionother
Placebo vehicle solution